

### Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

### Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease

Jun 18 2019, 8:29 AM EDT

### Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease

May 21 2019, 8:00 AM EDT

### Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

May 14 2019, 8:00 AM EDT

### Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	226.64m
Last Price	\$4.61
52-Week	\$4.395 - \$17.25

06/25/2019 04:00 PM EDT

### Investor Relations

Sofia Warner  
 Director, Investor Relations  
 T: +1 (646) 813-4710  
[swarner@abeonatherapeutics.com](mailto:swarner@abeonatherapeutics.com)

### Management Team

#### João Siffert, MD

Chief Executive Officer, Head of Research & Development and Chief Medical Officer

#### Timothy J. Miller, PhD

President & Chief Scientific Officer

#### Christine Silverstein

Chief Financial Officer

#### Max Colao

Chief Commercial Officer

#### Edward Carr

Chief Accounting Officer

#### Juan Ruiz, MD, PhD

Head of European Medical Affairs

#### Neena Patil

Senior Vice President, General Counsel and Corporate Secretary

#### Jay Bircher

Senior Vice President, Quality & Technical Operations

#### Kristina Maximenko

Vice President, Human Resources

#### Scott Nogi

Vice President, Business Operations

### Abeona Therapeutics, Inc.

1330 Avenue of the Americas  
 33rd Floor  
 New York, NY 10019

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.